ESMO/ASCO recommendations for a Global Curriculum (GC) in medical oncology-edition 2016 by Dittrich, C et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2016
ESMO/ASCO recommendations for a Global Curriculum (GC) in medical
oncology-edition 2016
Dittrich, C; Kosty, M; Jezdic, S; Pyle, D; Berardi, R; Bergh, J; El Saghir, N; Lotz, J-P; Österlund, P;
Pavlidis, N; Purkalne, G; ESMO/ASCO Global Curriculum Working Group
DOI: 10.1093/annonc/mdw239
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: http://doi.org/10.5167/uzh-130791
Veröffentlichte Version
 
 
Originally published at:
Dittrich, C; Kosty, M; Jezdic, S; Pyle, D; Berardi, R; Bergh, J; El Saghir, N; Lotz, J-P; Österlund,
P; Pavlidis, N; Purkalne, G; ESMO/ASCO Global Curriculum Working Group (2016). ESMO/ASCO
recommendations for a Global Curriculum (GC) in medical oncology-edition 2016. Annals of Oncology,
27(8):1378-1381. DOI: 10.1093/annonc/mdw239
Annals of Oncology 27: 1378–1381, 2016
doi:10.1093/annonc/mdw239
ESMO/ASCO recommendations for
a Global Curriculum (GC) in medical
oncology—edition 2016
Oncology is driven by an exponentially increasing complexity.
As an example, the use of molecular proﬁling or the determin-
ation of molecularly based biomarkers for the selection of the
appropriate targeted therapy has now become routine in clinical
practice. Such developments must be covered during education
and integrated at all levels, from basic medical oncology at the
initial postgraduate level to advanced levels requiring specialised
approaches at the level of continuing medical education [1].
Consequently, and in line with the internationalisation of
healthcare in general and higher mobility of physicians and
patients, the European Society for Medical Oncology (ESMO)
and the American Society of Clinical Oncology (ASCO) have
identiﬁed the need for a set of international recommendations
for the clinical training of physicians that deﬁne the standard of
qualiﬁcations, i.e. to specify the requirements to be fulﬁlled to
qualify them as medical oncologists. Adherence to the Global
Curriculum (GC) is to ensure that patients, wherever they live,
have an equal chance of receiving treatment from well-trained
physicians respecting multidisciplinarity, to which both ESMO
and ASCO are strongly committed.
The fundamental pillar is a common requirement of 5 years
of training. This training period includes a minimum of 2 years
in internal medicine followed by a minimum of 2 years of
medical oncology. Also within these 5 years, half a year may be
dedicated to clinical research that should create the basis for
trainees’ critical assessment and their continuous internalisation
of new developments in the ﬁeld.
In 2011, the European Commission based its formal recogni-
tion of medical oncology on the recommendations made by the
ESMO/ASCO GC Task Force. Thus, medical oncology has been
included among the medical specialities covered by the
Directive 2005/36/EC on the recognition of professional qualiﬁ-
cations [2, 3]. The fact that the European Commission accepted
the requirement of a minimum of 5 years of specialisation led
many countries to adopt a 5-year period for training in medical
oncology.
The training requirements detailed in the GC apply to profes-
sionals across the globe and reinforce the position of ESMO and
ASCO as leading organisations for oncology [4, 5]. The GC
2016 is a visible sign that these two societies, who cooperatively
prepared this edition, are simultaneously advocating for and
acting as reliable sources of education in medical oncology and
encouraging a multidisciplinary approach to cancer care.
background
Medical oncology as a speciality was established in 1965, after
ASCO was founded in the United States in 1964. A uniform
system of training in medical oncology in the United States was
formulated by the American Board of Internal Medicine in 1973
[6]. In 1998, ASCO published a training resource document for
development of a curriculum in medical oncology [7].
In 1989, ESMO started an examination programme in
medical oncology for physicians actively working in the ﬁeld. To
guarantee the maintenance and updating of the knowledge, skills,
and attitudes of these physicians, that is essential to the provision
of quality care, a programme of continued education inmedical on-
cology, the ESMO Medical Oncologist’s Recertiﬁcation Approval
(MORA) programme, was introduced in 1994 [8].
Both ESMO and ASCO support ongoing professional devel-
opment in medical oncology as part of their missions. As the
leading oncology professional societies worldwide, visible by the
signiﬁcant number of international members and attendees at
their meetings, and due to the increasingly global nature of
cancer care and the increased international interest in the ﬁeld,
a GC was perceived by both societies as an important joint
project. Since 2002, ESMO and ASCO have been working to-
gether to develop common recommendations for training in
medical oncology to overcome barriers in the quality of care.
GC: editions 2004 and 2010
In 2004, a joint ESMO/ASCO GC Task Force established the ﬁrst
Global Core Curriculum outline for training in medical oncology.
This outline was distributed to universities and medical onco-
logy societies and was simultaneously published in the Annals of
Oncology and the Journal of Clinical Oncology [9, 10].
Interest in using the Global Core Curriculum outline has
increased considerably since its inception, as shown by the avail-
ability of translations into a range of different languages avail-
able on the ESMO and ASCO websites [11, 12]. It was also used
as a model for development of the speciality of medical onco-
logy in several countries around the world. Additionally, a Log-
Book was launched as a support tool for medical oncologists in
training with the purpose of keeping a record of oncology trai-
nees’ educational programmes and their progress and providing
supervisors with a tool to assess performance [13, 14]. The GC
was updated in 2010, and the Log-Book has been updated by
the GC Working Group (WG), a group that evolved from the
previous Task Force, to reﬂect continuous commitment to edu-
cation of trainees in medical oncology [15–18].
The 2010 edition presented a broad range of recommenda-
tions to be adopted by national educational and healthcare au-
thorities and to be implemented according to the resources and
conditions of each country. The GC WG recognised that the di-
versity of health and educational systems around the world may
have rendered some curriculum recommendations aspirational
at the stage of its implementation, even for those systems with
well-developed training programmes in medical oncology, but
that were, nevertheless, worth pursuing further.
The intention of the propagation of a GC was and is to iden-
tify and reduce the degree of heterogeneity of the medical
content and also, at the organisational level, the duration and
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structure of the internal medicine part of the training in medical
oncology in Europe [19]. According to data assessed by the
ESMO/ASCO GC European landscape survey on the evolution
of medical oncology training in Europe, medical oncology is
recognised as a separate speciality in 23 countries. The GC
recommendations were adopted in nine countries, adapted in
seven countries, and this process was ongoing in two other
countries [19].
logistic development
The 2004 edition of the GC was drafted by the chair and the re-
spective members of the GC Task Force. The system of learning
outcomes based on awareness, knowledge, and competence was
developed only in the accompanying Log-Book [13, 14].
The updated 2010 edition of the GC was drafted by several
oncologists upon invitation from the GC Task Force. This
edition was reviewed by a panel of experts from both societies.
The use of a categorisation of awareness, knowledge, and com-
petence was restricted to the Log-Book.
Planning for the 2016 edition of the GC started in May 2015,
ﬁrst by the GC WG and later on, an ad hoc editorial board,
which was composed of GC WG representatives from both
ESMO and ASCO, was responsible for further selection of the
topics and the authors of the respective contributions. All con-
tributions underwent extensive anonymised expert review.
GC 2016: changes in form and content
The major change in the 2016 edition consists of the adoption
of acknowledged pedagogical principles. This resulted in a tem-
plate-based format for the learning objectives, wherever appro-
priate. Thus, the qualities of the learning objectives have been
divided into the subcategories of awareness, knowledge, and
skills. This holds true primarily for the training in the different
tumour entities, and, where possible, the more general teaching
items are also subjected to this new format to a large extent.
In recent years, important advances in medical oncology have
been achieved. The unequivocal demands of personalised or
precision medicine on the one side and of completely different
developments, like the perpetually increasing survivorship com-
munity, on the other side—to mention just two examples of
recent changes in oncology—have led to the development of the
GC 2016 edition [20]. With regard to content, multiple changes
and innovations were integrated, such as:
• targeted therapies have been integrated into the (sub)chapters
of the separate tumour entities, wherever suitable, to match
the clinical reality;
• immunotherapy is presented in a separate chapter to reﬂect
its actual impact;
• biological therapy and immunotherapy are now presented as
separate chapters;
• pathology, molecular pathology, laboratory medicine, transla-
tional research, and principles of personalised cancer medi-
cine, which all previously belonged to the subsection ‘Basic
principles in the management and treatment of malignant
diseases’, have been transformed into separate chapters due to
their importance, accepting some unavoidable overlap;
• clinical research and statistics have been split into separate
chapters under ‘Basic scientiﬁc principles’;
• tumour immunology has been separated into ‘Tumour im-
munology’, which has been kept under ‘Basic scientiﬁc princi-
ples’, and into ‘Immunotherapy’, which has been moved as a
separate chapter to ‘Therapy’;
• imaging and molecular imaging have been separated into two
chapters and are followed by an additional chapter on
‘RECIST’;
• rare cancers have been established as a novel subsection;
• cancer treatment in patients with comorbidities is dealt with
in a new subsection;
• genetic counselling is given increased attention as a separate
section due to its emerging role in routine clinical practice;
• survivorship, with its tremendously increasing impact, is also
now presented in a separate section.
With regard to culturally sensitive contents, like supportive
measures, palliative care, end-of-life-care, geriatric oncology,
psychosocial aspects of cancer, patient education, survivorship,
as well as bioethical, legal, and economic issues, positions were
reserved to be ﬁlled by representatives from both societies. In
particular, these authors were asked to take into account the
global nature of the curriculum.
Altogether, the GC 2016 consists of 12 sections comprising
17 subsections, 44 chapters, and 35 subchapters, provided by 96
different authors, among them 64 primarily ESMO-related and
32 primarily ASCO-related.
next steps of deployment for ESMO
and ASCO
The GC 2016 will be released at the next annual ESMO
Congress 2016 in Copenhagen, and a corresponding Log-Book
will be released in 2017 [11, 12].
The target population of the GC is primarily university teach-
ing staff, mentors of medical oncology training programmes,
and young medical oncologists in training. The GC WG intends
to work closely with the respective national medical oncology
societies via the ESMO national representatives and to seek their
endorsement of the GC 2016. In addition, ESMO and ASCO
also invite practising oncologists and clinicians, and even na-
tional health authorities and politicians, to become familiar
with the 2016 edition. The so-called ‘implementation symposia’
will serve to efﬁciently implement the GC 2016 in the various
oncologic communities.
To assess the impact of the GC 2016 on the training landscape
in medical oncology—this time not restricted to Europe [19]—
the GC WG has envisaged performing a global GC landscape
survey therewith monitoring its actual baseline status, i.e. the
status before implementation of the GC 2016.
future outlook
The development and registration of increasingly expensive
drugs force all national economies to develop a cost-effective use
of these cancer drugs. Both societies have presented their posi-
tions regarding a rational approach to deal with an economic at-
titude versus options for cancer treatment [21, 22]. This reﬂects
Volume 27 | No. 8 | August 2016 doi:10.1093/annonc/mdw239 | 
Annals of Oncology editorials
 at U
ZH
 H
auptbibliothek / Zentralbibliothek ZÃ¼rich on January 10, 2017
http://annonc.oxfordjournals.org/
D
ow
nloaded from
 
in a very concrete way what is described as the shift of the old
social contract of the Harrison-era that emphasised patient care
to the new social contract in our actual managed-care era that
emphasises cost containment and efﬁciency [23, 24]. Awareness
and detailed, up-to-date knowledge of this additional dimension
of cancer care also need to be included in future medical oncol-
ogy education to guarantee sustainable cancer care, as already
required in the corresponding subchapter on economic issues of
new cancer drugs in the GC 2016 [1].
This leads to an altered view of medical education, not only as
far as the content is concerned but also regarding the teaching
and assessment strategies. Both content and trustworthy profes-
sional activities are meticulously assigned to the speciﬁed learn-
ing outcome categories [25, 26].
After having carried out the major step of harmonisation of
the learning requirements to qualify as a medical oncologist, the
GC WG is endorsing the next logical step of harmonising the
teaching and assessment strategies.
A plethora of learning mechanisms and instruments exists,
including Internet-based tools such as YouTube videos or the
iTune U educational app, comprised of a variety of products
with partly complementary and partly overlapping content. The
GC WG will have to select adequate teaching material covering
all content required by the GC and to be aware of new areas
which should be covered in a timely manner by its carrier soci-
eties. Although going beyond the main mission of the GC WG,
both societies take care of leaders generation programmes to
complement those skills not necessarily being covered by the
GC, such as managerial skills. With the corresponding Log-
Book, a harmonised instrument for assessment will be provided
soon. In order to also react appropriately in this area to the
internationalisation on the one side and increasing specialisa-
tion on the other, a compilation of subdivided assessments
carried out at dislocated teaching settings (e.g. accredited
courses on speciﬁc topics) and via different accredited teaching
providers may be considered as a strategy.
Due to a broadened perspective of the GC WG, it will embark
on initiatives in geographical areas of future interest for the soci-
eties to contribute to harmonisation of the training in medical
oncology worldwide.
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